Plain-English summary
Court says branded drug maker failed to plead induced infringement against a generic that carved out the patented use
The Court unanimously reversed the Federal Circuit and held that Amarin’s complaint did not plausibly allege that Hikma induced infringement of Amarin’s patented uses. Because Hikma’s label excluded the patented use, Amarin’s allegations about calling the product “generic” and citing public sales data were insufficient to survive a motion to dismiss under 35 U.S.C. §271(b).
Why this matters
The decision clarifies when a branded drug maker can sue a generic manufacturer for inducing infringement of a method-of-use patent after the generic’s label excludes the patented use. It sets a higher pleading standard for induced infringement claims in this common pharmaceutical context, reducing the chance that routine statements about a product or public sales figures will trigger patent litigation.
Who may feel it
- Generic drug manufacturers
- Brand-name pharmaceutical companies
- Patent holders and patent litigators
- Physicians and pharmacists (indirectly, via labeling and litigation effects)
- Health care payers and patients (indirectly, through drug availability and costs)